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regard reliable biomarkers of response, ideally to be used as 
early surrogate endpoints for assessing response are much 
needed. Our results suggest that as early as at a three weeks 
interval from RT and ipilimumab, peripheral blood markers 
predict for development of a clinical objective response to 
the combination. 
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The use of PET/CT has increased much in the last decade, 
from a purely diagnostic to a radiotherapy planning and 
therapy monitoring tool. For these new applications, the 
quantitative and objective exploitation of PET/CT datasets 
becomes crucial given the well-established limitations of 
visual and manual analysis. Within this context, the 
Radiomics approach which consists in extracting large amount 
of information from multimodal images relies on a complex 
pipeline: image pre-processing, tumor segmentation, image 
analysis for shape and heterogeneity features calculation, 
and machine learning for robust and reliable features 
selection, ranking and combination with respect to a clinical 
endpoint. Although the Radiomics approach has been 
extensively applied to CT imaging, its use for PET/CT is more 
recent and less mature. There are however already a large 
body of published works hinting at the potential value of 
textural features and other advanced image features 
extracted from PET/CT in numerous tumour types. However, 
many methodological issues and limitations specific to 
PET/CT image properties have been highlighted by recent 
studies, This presentation aims at presenting both the 
promises and potential of advanced PET/CT image textural 
features analysis to build prognostic and predictive models, 
as well as the numerous pitfalls to avoid in order to further 
advance research in that promising field. 
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In the era of tailored medicine, the field of radiation 
oncology aims at identifying patients likely to benefit from 
treatment intensification and of those suffering from 
undesired treatment-related side-effects. In the past, patient 
selection in oncology was merely based on, e.g., 
randomisation, immunohistochemical staining of tumour 
biopsies, on tumour size or stage, or even on preferences. 
The introduction and increased availability of high-
throughput techniques, such as genomics, metabolomics and 
Next Generation Sequencing, have revolutionised the field.  
In radiation oncology, high-quality anatomical and functional 
imaging is, besides physical examination, the pillar for 
target-volume delineation, planning and response 
assessment. Therefore, ‘radiomics’, referring to the 
comprehensive quantification of tumour phenotypes through 
extensive image features analyses, is a logical consequence. 
Pioneered by the publication of Aerts et al. [1], the field is 
rapidly evolving regarding techniques, tumour sites and 
imaging modalities assessed.  
In this presentation, the status of radiomics for radiotherapy 
individualisation will be highlighted and possible areas of 
future research activities outlined.  
References: [1] Aerts HJWL, Rios Valezques E, Leijenaar RTH, 
et al. Decoding tumour phenotype by noninvasive imaging 
using a quantitative radiomics approach. Nature 
Communications 5, Article number: 4006. 
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Purpose or Objective: Molecular profiling is considered 
standard of care for advanced non-small cell lung cancer 
(NSCLC) patients. Approximately 25% of adenocarcinoma 
patients has a KRAS mutation; 10-15% has an activating EGFR 
mutation where tyrosine kinase inhibitors (TKI) are approved 
for first line treatment. EGFR and KRAS mutations are 
mutually exclusive. Obtaining enough tissue for molecular 
analysis may be difficult. Therefore, in this study we 
investigated whether EGFR and KRAS mutations can be 
distinguished from wildtype patients based on features 
derived from standard CT imaging. 
 
Material and Methods: From a retrospective database of 
NSCLC patients included between 2004 and 2014, all EGFR-
mutated (EGFR+, only exon 19 deletions or exon 21 L858R) 
patients, the consecutive KRAS-mutated (KRAS+) and 
EGFR/KRAS wildtype (WT) patients were included. The CT-
scan at first diagnosis of NSCLC (i.e. before any treatment) 
with the primary tumor visible was used for radiomics feature 
extraction. The primary tumor was delineated using a 
GrowCut segmentation algorithm (3D Slicer) and manually 
